A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Overview
- Phase
- Phase 3
- Intervention
- Ruxolitinib
- Conditions
- Pancreatic Cancer
- Sponsor
- Incyte Corporation
- Enrollment
- 86
- Primary Endpoint
- Overall Survival (OS)
- Status
- Terminated
- Last Updated
- 8 years ago
Overview
Brief Summary
This was to determine the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of metastatic pancreatic cancer.
Detailed Description
This was a randomized, double-blinded, placebo-controlled, Phase 3 study, in which approximately 270 participants with advanced or metastatic adenocarcinoma of the pancreas who had failed or were intolerant to first-line chemotherapy were to be randomized (1:1) to one of the following treatment groups: * Treatment A (N = 135): Capecitabine + ruxolitinib * Treatment B (N = 135): Capecitabine + placebo Treatment consisted of repeating 21-day cycles. Capecitabine was self-administered for the first 14 days of each cycle, and ruxolitinib/placebo was self-administered during the entire cycle. Treatment for all participants was to continue as long as the regimen was tolerated, and the participant did not meet discontinuation criteria. Participants who discontinued treatment continued to be followed for subsequent anticancer treatments and survival.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically or cytologically confirmed adenocarcinoma of the pancreas.
- •Advanced adenocarcinoma of the pancreas that is inoperable or metastatic.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- •Received 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy).
- •≥ 2 weeks elapsed from the completion of previous treatment regimen and participants must have recovered or be at a new stable baseline from any related toxicities.
- •Radiographically measurable or evaluable disease
- •An modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:
- •Criteria:
- •mGPS of 1: C-reactive protein (CRP) \> 10 mg/L and albumin ≥ 35 g/L
- •mGPS of 2: CRP \> 10 mg/L and albumin \< 35 g/L
Exclusion Criteria
- •Received more than 1 prior regimen for advanced or metastatic disease.
- •Ongoing radiation therapy, radiation therapy administered within 30 days of enrollment
- •Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor embolization).
- •Current or previous other malignancy within 2 years of study entry without sponsor approval
- •Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase deficiency (DPD), or other known hypersensitivity to active substances, including fluorouracil (5-FU), ruxolitinib, or any of their excipients.
- •Prior treatment with a JAK inhibitor for any indication.
Arms & Interventions
Ruxolitinib plus capecitabine
Intervention: Ruxolitinib
Ruxolitinib plus capecitabine
Intervention: Capecitabine
Placebo plus capecitabine
Intervention: Placebo
Placebo plus capecitabine
Intervention: Capecitabine
Outcomes
Primary Outcomes
Overall Survival (OS)
Time Frame: Randomization until death due to any cause up to 6-months or to the data cutoff 11FEB2016.
Overall survival is reported here based on the number of deaths from randomization until the data cut-off.
Secondary Outcomes
- Progression Free Survival (PFS)(Randomization to disease progression, or death due to any cause if sooner; up to 6-months or to the data cutoff 11FEB2016.)
- Percentage of Participants Achieving Progression Free Survival (PFS)(Randomization to disease progression, or death due to any cause if sooner; up to 6-months or to the data cutoff 11FEB2016.)
- Objective Response Rate (ORR)(Baseline through end of study; up to 6-months or to the data cutoff 11FEB2016.)
- Duration of Response(Baseline through end of study; up to 6-months or to the data cutoff 11FEB2016.)
- Participants With Treatment-Emergent Adverse Events (TEAEs)(Baseline through approximately 30 days post treatment discontinuation; up to 6-months or to the data cutoff 11FEB2016.)